Hornet Therapeutics: Breakthrough in EBV-Related Disease Prevention

Hornet Therapeutics Ltd, a biotech startup originating from University Basel, recently unveiled groundbreaking data on HTX-201, an IDO1 blocker designed to combat diseases triggered by Epstein-Barr virus. The company's entrance into the clinical testing phase signals a potential revolution in EBV-related disease prevention.

Indoleamine 2,3-dioxygenase 1 (IDO1) has emerged as a key target for cancer therapy due to its immunosuppressive properties. Several IDO1 inhibitors are already in clinical trials, presenting a promising avenue for cancer treatment.

Recent findings published in Science shed light on EBV's exploitation of NAD biosynthesis via IDO-1-driven metabolic pathways to support infected B cells. By inhibiting IDO-1, Hornet Therapeutics aims to disrupt this process and hinder EBV-driven pathogenesis, offering a preventive strategy for EBV-associated diseases, including lymphomas.

The inability to develop a specific small molecule targeting EBV has plagued antiviral research for years. However, with HTX-201 showing promising results, Hornet Therapeutics is on track to initiate Phase I/II trials focusing on solid organ transplant recipients within the next 18 months. This innovative approach holds potential for addressing unmet needs in managing EBV-related diseases.

The team at Hornet Therapeutics, led by Dr. Fraser Gray and Professor Christoph Hess, is well-equipped to navigate the complexities of antiviral drug development. Their expertise positions the company as a frontrunner in combating EBV-related diseases and exploring additional treatment avenues for conditions like MS and long-COVID.